Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
08/2000
08/03/2000WO2000044893A1 In vitro activated gamma delta lymphocytes
08/03/2000WO2000044888A2 Dimethylarginine dimethylaminohydrolases
08/03/2000WO2000044880A1 Means for inducing or increasing the immunogenicity of myeloid acute leukemia cells
08/03/2000WO2000044788A1 Production of tetravalent antibodies
08/03/2000WO2000044782A2 Ewing's tumour antigen, nucleic acid and antibodies
08/03/2000WO2000044777A1 Antibodies specific to kdr and uses thereof
08/03/2000WO2000044774A2 Inhibition of stat3 signal transduction for human cancer therapy
08/03/2000WO2000044762A1 5-GLYCOSYLOXY-6-HYDROXYNAPHTHO[2,3-f]QUINOLINE-7,12-DIONE HAVING ANTICANCER ACTIVITIES
08/03/2000WO2000044757A1 Hesperitin pro-forms with enhanced bioavailability
08/03/2000WO2000044750A1 PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND Iλ-A$g(a)
08/03/2000WO2000044740A2 Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
08/03/2000WO2000044739A1 Reverse hydroxamate inhibitors of matrix metalloproteinases
08/03/2000WO2000044730A1 2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors
08/03/2000WO2000044728A1 Substituted bicyclic derivatives useful as anticancer agents
08/03/2000WO2000044718A1 Carotenoid degradation products having an anti-tumoral effect
08/03/2000WO2000044715A1 Novel aralkylguanidine compounds
08/03/2000WO2000044711A1 ACETYLENIC $G(b)-SULFONAMIDO AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS
08/03/2000WO2000044710A2 Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
08/03/2000WO2000044407A2 Materials and methods to inhibit hodgkin and reed sternberg cell growth
08/03/2000WO2000044404A2 Methods for inhibiting brain tumor growth by using selected integrin antagonists
08/03/2000WO2000044403A1 Her-2 binding antagonists
08/03/2000WO2000044401A1 Use of a melanoma inhibiting activity factor (mia) for cartilage and bone repair
08/03/2000WO2000044398A2 Methods for increasing circulating platelets for collection and cryopreservation using thrombopoietin compositions
08/03/2000WO2000044392A2 Identification of specific differentially expressed mycobacterial antigens
08/03/2000WO2000044391A2 Plasminogen kringle 4 region fragments and methods of use
08/03/2000WO2000044389A2 Method for preparing membrane vesicles
08/03/2000WO2000044384A1 USE OF PYRIDAZINO[4,5-b]INDOLE-1-ACETAMIDE DERIVATIVES FOR PREPARING MEDICINES FOR TREATING DISEASES RELATED TO THE DYSFUNCTION OF PERIPHERAL BENZODIAZEPIN RECEPTORS
08/03/2000WO2000044375A1 Antioxidant compositions and methods for companion animals
08/03/2000WO2000044364A2 P53 inhibitors and their use for the treatment of cancer, hyperthermia, hypoxia, a burn, trauma to the central nervous system, a seizure, acute inflammation, tissue ageing, preservation of organs for transplant and preparation of a host for bone marrow transplant
08/03/2000WO2000044362A2 The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation
08/03/2000WO2000044350A1 Transnasal transport/immunisation with highly adaptable carriers
08/03/2000WO2000032175A3 METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY
08/03/2000WO2000027874A3 Nucleic acids encoding transferrin receptor-like proteins and products related thereto
08/03/2000WO2000024896A3 Biological material for preparing pharmaceutical compositions for treating mammals
08/03/2000WO2000024415A3 Methods for regulating angiogenesis and vascular integrity using trk receptor ligands
08/03/2000WO2000023407A3 Ureido-thiobutyric acid derivatives as ppar-agonists
08/03/2000WO2000023105A3 Adjuvant systems and vaccines
08/03/2000WO2000022137A3 Selectively replicating viral vectors
08/03/2000WO2000021926A3 6-SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS
08/03/2000WO2000014240A3 Attenuated salmonella sp12 mutants as antigen carriers
08/03/2000WO2000009691A9 Bpc-1: a secreted brain specific protein expressed and secreted by prostate and bladder cancer cells
08/03/2000WO2000009675A9 Adenovirus formulations for gene therapy
08/03/2000WO2000009549A9 Peripheral-type benzodiazepine receptor associated proteins, cloning, expression and methods of use
08/03/2000WO2000006589A9 Prostate derived ets factor
08/03/2000WO2000006185A3 Methods of using lanreotide, a somatostatin analogue
08/03/2000WO1999063975A3 A method for stimulating the immune system
08/03/2000WO1999062941A8 Serpentine transmembrane antigens expressed in human cancers and uses thereof
08/03/2000WO1999015130A3 Synthetic antineoplastic agents derived from dolastatin 15 and methods of making same
08/03/2000DE19903495A1 Ewing-Tumor-Antigen und Nukleinsäure Ewing's tumor antigen and nucleic acid
08/03/2000DE19903095A1 Gewinnung von gamma-Linolensäure aus Protozoen der Gattung Colpidium Production of gamma-linolenic acid from protozoa of the genus Colpidium
08/03/2000CA2361624A1 5-glycosyloxy-6-hydroxynaphtho[2,3-f]quinoline-7,12-dione having anticancer activities
08/03/2000CA2361621A1 Inhibition of stat3 signal transduction for human cancer therapy
08/03/2000CA2361553A1 Antibodies specific to kdr and uses thereof
08/03/2000CA2361518A1 Purine inhibitors of cyclin dependent kinase 2 and ikb-.alpha.
08/03/2000CA2361260A1 Methods for increasing circulating platelets for collection and cryopreservation using thrombopoietin compositions
08/03/2000CA2361246A1 Identification of specific differentially expressed antigens
08/03/2000CA2360997A1 Non-invasive method for detecting target rna
08/03/2000CA2360752A1 Method for preparing membrane vesicles
08/03/2000CA2360690A1 Plasminogen kringle 4 region fragments and methods of use
08/03/2000CA2360671A1 P53 inhibitors and therapeutic use of the same
08/03/2000CA2360643A1 Transnasal transport/immunisation with highly adaptable carriers
08/03/2000CA2360374A1 Comp/tsp-1, comp/tsp-2 and other tsp chimeric proteins
08/03/2000CA2360146A1 Methods for inhibiting brain tumor growth by using selected integrin antagonists
08/03/2000CA2359994A1 Production of tetravalent antibodies
08/03/2000CA2359701A1 Nucleic-acid binding proteins
08/03/2000CA2359317A1 Method of treating restenosis by antisense targeting of c-myc
08/03/2000CA2358967A1 Hesperitin pro-forms with enhanced bioavailability
08/03/2000CA2356855A1 Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
08/03/2000CA2356481A1 Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
08/03/2000CA2356345A1 Acetylenic beta-sulfonamido and phosphinic acid amide hydroxamic acid tace inhibitors
08/03/2000CA2356313A1 Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors
08/03/2000CA2356267A1 2,3,4,5-tetrahydro-1h-¬1,4|benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors
08/02/2000EP1024199A2 Recovery of gamma-linolenic acid from protozoa of the genus Colpidium
08/02/2000EP1024197A2 Mesothelial cell gene therapy
08/02/2000EP1024145A2 Novel azalides and methods of making same
08/02/2000EP1023906A1 Potentiator for antibody against lymphoid tumor
08/02/2000EP1023447A1 Human ribonuclease a with reduced ribonuclease inhibitor affinity
08/02/2000EP1023444A1 Cell division regulators
08/02/2000EP1023323A1 Novel vitamin d receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof
08/02/2000EP1023318A1 Dipeptides for the treatment of diseases related to the biological effect of endothelin
08/02/2000EP1023315A1 Methods and compositions for destruction of selected proteins
08/02/2000EP1023313A1 Inhibition of stress activated protein kinase (sapk) pathway and sensitization of cells to cancer therapies
08/02/2000EP1023302A1 Binuclear complex
08/02/2000EP1023282A1 Novel pharmaceutically active compounds, their preparation and use as ece-inhibitors
08/02/2000EP1023277A1 Novel 3,4-diarylthiazolin-2-one or -2-thione derivatives, preparation methods and uses in therapy
08/02/2000EP1023268A1 Isoquinolines as urokinase inhibitors
08/02/2000EP1023263A1 Novel vitamin d analogues
08/02/2000EP1023082A1 Tumour vaccine
08/02/2000EP1023080A1 Ligand binding site of rage and uses thereof
08/02/2000EP1023073A1 Vitronectin receptor antagonist
08/02/2000EP1023066A1 Novel pyrazole and pyrazoline substituted compounds
08/02/2000EP1023063A1 INDENO 1,2-c]-, NAPHTHO 1,2-c]- AND BENZO 6,7]CYCLOHEPTA 1,2-c]PYRAZOLE DERIVATIVES
08/02/2000EP1023061A1 Somatostatin agonists
08/02/2000EP1023050A1 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
08/02/2000EP1022951A1 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
08/02/2000EP0923642A4 Active survival domains of igf-ir and methods of use
08/02/2000EP0885229B1 Fused pyrrolo(2,3-c)carbazole-6-ones which potentiate activity of gamma interferon
08/02/2000EP0819129B1 Pyrazole derivatives and processes for the preparation thereof
08/02/2000EP0613373B1 Risedronate delayed-release compositions
08/02/2000CN1261895A Cyclic azapeptide with angiogenic effect
1 ... 1891 1892 1893 1894 1895 1896 1897 1898 1899 1900 1901 1902 1903 1904 1905 1906 1907 1908 1909 1910 1911 ... 2211